Challenges and Opportunities to Updating Prescribing Information for Longstanding Oncology Drugs

被引：2

作者：

Balogh, Erin P. ^{[1
]}

Bindman, Andrew B. ^{[2
]}

Eckhardt, S. Gail ^{[3
]}

Halabi, Susan ^{[4
]}

Harvey, R. Donald ^{[5
]}

Jaiyesimi, Ishmael ^{[6
]}

Miksad, Rebecca ^{[7
]}

Moses, Harold L. ^{[8
]}

Nass, Sharyl J. ^{[1
]}

Schilsky, Richard L. ^{[9
]}

Sun, Steven ^{[10
]}

Torrente, Josephine M. ^{[11
]}

Warren, Katherine E. ^{[12
]}

机构：

[1] Natl Acad Sci Engn & Med, Hlth & Med Div, 500 Fifth St NW, Washington, DC 20001 USA

[2] Univ Calif San Francisco, San Francisco, CA 94143 USA

[3] Univ Texas Austin, Dell Med Sch, Austin, TX 78712 USA

[4] Duke Univ, Durham, NC USA

[5] Emory Univ, Atlanta, GA 30322 USA

[6] Beaumont Hosp, Royal Oak, MI USA

[7] Flatiron Hlth, New York, NY USA

[8] Vanderbilt Univ, 221 Kirkland Hall, Nashville, TN 37235 USA

[9] Amer Soc Clin Oncol, Alexandria, VA USA

[10] Janssen Res & Dev, Raritan, NJ USA

[11] Hyman Phelps & McNamara PC, Washington, DC USA

[12] Dana Farber Boston Childrens Canc & Blood Disorde, Boston, MA USA

来源：

ONCOLOGIST | 2020年 / 25卷 / 03期

关键词：

Cancer; Drug prescriptions; Drug legislation; Drug approval; Pharmaceutical research;

D O I：

10.1634/theoncologist.2019-0698

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

A number of important drugs used to treat cancer-many of which serve as the backbone of modern chemotherapy regimens-have outdated prescribing information in their drug labeling. The Food and Drug Administration is undertaking a pilot project to develop a process and criteria for updating prescribing information for longstanding oncology drugs, based on the breadth of knowledge the cancer community has accumulated with the use of these drugs over time. This article highlights a number of considerations for labeling updates, including selecting priorities for updating; data sources and evidentiary criteria; as well as the risks, challenges, and opportunities for iterative review to ensure prescribing information for oncology drugs remains relevant to current clinical practice.

引用

页码：E405 / E411

页数：7

共 50 条

[41] Prescribing of bisphosphonates and antibiotics in Pakistan: challenges and opportunities for the future
Riaz, Humayun
Godman, Brian
Hussain, Shahzad
Malik, Farnaz
Mahmood, Sidra
Shami, Ali
Bashir, Sajid
JOURNAL OF PHARMACEUTICAL HEALTH SERVICES RESEARCH, 2015, 6 (02) : 111 - 121
[42] Opportunities and Challenges of Defining “Value” in Oncology Care
Nicole M. Mott
Lesly A. Dossett
Annals of Surgical Oncology, 2022, 29 : 6518 - 6519
[43] Emerging Opportunities and Challenges of Biosimilars in Oncology Practice
Lyman, Gary H.
JOURNAL OF ONCOLOGY PRACTICE, 2017, 13 (09) : 7S - +
[44] Challenges and Opportunities With Oncology Drug Development in China
Bajaj, Gaurav
Gupta, Manish
Wang, Hwei-Gene Heidi
Barrett, Jeffrey S.
Tan, Matthew
Rupalla, Katrin
Bertz, Richard
Sheng, Jennifer
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2019, 105 (02) : 363 - 375
[45] Engineering and physical sciences in oncology: challenges and opportunities
Michael J. Mitchell
Rakesh K. Jain
Robert Langer
Nature Reviews Cancer, 2017, 17 : 659 - 675
[46] Prescribing patient information leaflets may be better than prescribing drugs
Kenny, T
Wilson, R
Purves, IN
BRITISH MEDICAL JOURNAL, 1998, 317 (7150): : 80 - 81
[47] Oncology drugs: dissemination of ADR information
Reactions Weekly, 2003, 979 (1) : 5 - 5
[48] Factors associated with prescribing restriction on oncology formulary drugs in Malaysia
Omotayo Fatokun
Michael N. Olawepo
International Journal of Clinical Pharmacy, 2016, 38 : 1075 - 1079
[49] Potential for value-based prescribing of oral oncology drugs
Ratain, M. J.
Lichter, A. S.
ANNALS OF ONCOLOGY, 2018, 29
[50] Factors associated with prescribing restriction on oncology formulary drugs in Malaysia
Fatokun, Omotayo
Olawepo, Michael N.
INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2016, 38 (05) : 1075 - 1079

← 1 2 3 4 5 →